Jürgen Floege, MD, senior professor at RWTH Aachen University’s Medical School

PREVAIL: Felzartamab’s Sustained Clinical Outcomes In IgAN, With Jurgen Floege, MD

Key research on felzartamab highlights the long-lasting effects of CD38-targeted therapy and its potential for improved outcomes in patients with 

, emphasizing the promise of immune-targeted treatment.

Data from the completed phase 2 study, IGNAZ, and ongoing phase 3 trial, PREVAIL, investigating the effect of an anti-CD38 agent, felzartamab, in IgAN patients, were presented by Jürgen Floege, MD, senior professor at RWTH Aachen University’s Medical School, at 

the American Society of Nephrology (ASN) Kidney Week 2025

IGNAZ phase 2 data showed felzartamab treatment successfully depleted plasma cells, while immunoglobulins recovered, IgA remained suppressed, proteinuria remained reduced, and galactose-deficient IgA (GDiGA) rebounded. The ongoing phase 3 PREVAIL trial aims to further evaluate efficacy and safety.

Over the past decade, the IgAN treatment landscape has evolved significantly. In 2015, Floege led the STOP-IgAN trial as principal investigator, describing the minimal benefits and potential harms of corticosteroids. Further research on anti-CD20 therapies, such as rituximab, demonstrated a lack of significant improvement in patient outcomes, suggesting B cells alone are insufficient drivers of pathogenic IgA. The phase 3 PROTECT trial showed the combination of renin-angiotensin system blockade with sparsentan reduced proteinuria and slowed GFR decline over 2 years, but did not alter immunoglobulin levels.

Against this backdrop, emerging immune-targeted therapies offer a novel approach to IgAN treatment. An investigational monoclonal antibody targeting CD38, felzartamab, depletes long-lived plasma cells involved in IgA production. In the phase 2 study, investigators noted patients were able to remain off treatment for up to 1.5 years, with the potential to maintain immunologic and biologic responses for even longer.

“With felzartamab, proteinuria reduction persists when you stop treatment, even for 1.5 years. As you destroy these long-lived plasma cells, all the immunoglobulins go down, but IgM and IgG go right back up to baseline. The moment you stop treatment, IgA stays low, whereas proteinuria stays low,” said Floegle in an interview with 

 “GDiGA reduces, so you can dissociate the treatment benefit from the course of IgA, a potentially important pathophysiological insight. Everybody now says IgA is what causes IgA nephropathy, but I'm not certain about that. And the study is yet another piece of evidence to nurture that doubt.”

PREVAIL, the ongoing 104-week phase 3 multicenter, randomized, double-blind, placebo-controlled trial, evaluates the efficacy and safety of felzartamab in adults with IgAN and consists of a 24-week treatment period where patients are randomly assigned to receive felzartamab or placebo, followed by an 80-week off-medication study.

The primary endpoint is the percent change in 24-hour UPCR at week 36, with a key secondary endpoint of change in eGFR at week 104. Further secondary endpoints included the percentage of participants achieving complete remission, safety, AEs, pharmacokinetics, and immunogenicity.

PREVAIL began enrollment in June 2025, recruiting 454 participants with biopsy-confirmed IgAN, with eGFR of ≥30mL/min/1.732, proteinuria of ≥1.0 g/day or UPCR ≥0.8 g/g.

“The question I am asked all the time is which drug for which patient. The drugs of the future are anti-APRIL, APRIL/BAFF inhibitors, or CD38 antibodies. Which one is better? I honestly don’t know. They have clear differences: anti-APRIL and APRIL/BAFF inhibitors require continuous administration, while CD38 therapies allow treatment pauses,” said Foegle. “In terms of clinical efficacy, they appear broadly similar. Hopefully, this competition will help reduce costs, which is a major concern. Another unresolved question is how to manage non-responders. Can you switch from one therapy to the other? I don’t think combination therapy makes sense, but if a patient fails anti-APRIL, could a CD38 antibody work, or vice versa? We will have to find out. There is still so much to learn.”

With 10 drugs in late-phase clinical development showing similar proteinuria reductions, there are new opportunities for patient and clinician's treatment choice. Further investigation into the long-lasting safety and efficacy of felzartamab for patients with IgAN will continue with phase 3 PREVAIL.

Editor’s Note: Floege reports relevant disclosures with AstraZeneca, Bayer, Biogen, and others.

Floege, J, Perkovic, V, Barratt, J, et al. PREVAIL: A Phase 3 Trial of Felzartamab in Adults With IgA Nephropathy. Presented at: ASN Kidney Week 2025; November 5–9, 2025; Houston, TX.

Rovin BH, Barratt J, Heerspink HJ L, et al. DUPRO Steering Committee and PROTECT Investigators. Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2‑year results from a randomised, active‑controlled, phase 3 trial. 

 2023;402(10417):2077‑2090. doi:10.1016/S0140‑6736(23)02302‑4. 

Videos

ASN insights on felzartamab, a CD38-targeted therapy, show sustained immune modulation in IgA nephropathy, offering a novel treatment approach.


Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Post Conference Perspectives

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

IgA Nephropathy

The HCPLive Berger disease page is a resource for medical news and expert insights on IgA nephropathy. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in Berger disease, and more.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Tim Smith joined the MJH Life Sciences team as an assistant editor for HCPLive in August 2022. He graduated from UC Berkeley with a degree in political science, working in multimedia journalism as a staff writer prior to joining MJH. In his spare time, he enjoys reading, watching TV, listening to podcasts, and rock climbing. You can contact him at 

Baricitinib shows early, clinically meaningful reductions in disease activity among post-menopausal women with 

2025 Fall Clinical Dermatology Conference

 in Las Vegas, Nevada, included a poster session at which these findings were presented. The data were authored by such investigators as Alia Abbas, MD, from the University of Alabama at Birmingham Medical Center Department of Dermatology.

Frontal fibrosing alopecia is a primary cicatricial alopecia is widely regarded as a clinical variant of lichen planopilaris (LPP). It is known to be characterized by inflammatory destruction of follicles along the frontotemporal scalp and eyebrow regions. The condition can also, ultimately, lead to irreversible hair loss and predominantly impacts post-menopausal women.

Frontal fibrosing alopecia has generally been resistant to standard topical and systemic treatments, prompting attention being drawn to more targeted approaches. A rising amount of data implicates the JAK/STAT pathway in frontal fibrosing alopecia's pathogenesis, leading to increasing exploration of Janus kinase (JAK) inhibitors as potential agents for those with this disease.

Abbas and colleagues conducted this proof-of-concept investigation to examine whether baricitinib, a JAK inhibitor, could mitigate ongoing disease activity and prevent additional disease progression in patients living with frontal fibrosing alopecia. They used a 36-week open-label trial design, recruiting women aged 18 years or older with biopsy-confirmed frontal fibrosing alopecia as participants in their research. These subjects were evaluated at baseline and at the 12, 24, and 36-week marks.

Abbas et al provided subjects with baricitinib 4 mg as an oral, once-daily monotherapy from Weeks 0 - 12. After this point, all participants continued with follow-up visits based on protocol. There were 20 women initially screened for participation. Five were shown not to meet the investigators' inclusion criteria, leaving 15 as eligible; by the time of interim analysis, 13 of these individuals had reached the 12-week evaluation point.

All of those enrolled in the analysis were post-menopausal and had biopsy-verified frontal fibrosing alopecia. The subjects each had documented failure of multiple prior therapy regimens as well. Over the 12-week period, clinically meaningful improvements were observed by Abbas and coauthors.

Patients' mean scores on the Lichen Planopilaris Activity Index (LPPAI), a composite measure of both symptoms and objective signs of the disease, were shown to have dipped substantially from 6.18 at screening to 2.26 by the 12-week mark.

 The investigative team noted the average reduction of 3.92 points attained statistical significance (

 < .05), suggesting a marked inflammatory disease activity decrease among those treated.

Improvements in the disease were also noted in patient-reported measures.

The PRO Scalp Hair Growth score rose from an average of 0.85 at baseline to 2.38 at the 12-week mark, suggesting a mean rise of 1.54 points (

 < .05). In contrast, Abbas et al found patient-perceived eyebrow growth, as captured by the PRO Eyebrow measure, indicated no shifts during the same time frame.

Symptoms of itch were evaluated by the team via a visual analogue scale (VAS) for pruritus.

 A decline in participants' average scores was observed, dipping from 4.38 to 3.46. This represented a reduction of 0.92 points, although this change did not meet the necessary threshold for statistical significance (

Overall, 12 weeks of baricitinib monotherapy led to early signals of efficacy in those living with refractory frontal fibrosing alopecia.

 While subjective eyebrow improvement notably absent by this point, subjects highlighted the presence of scalp hair growth perception along with modest reductions in pruritus. Longer follow-up was noted by Abbas and colleagues as required to determine whether these early gains translate into measurable regrowth.

To find out more information on topics such as those covered at Fall Clinical, view the latest coverage of conference.

Abbas A, Downing T, Elewski B, et al. Baricitinib in the Treatment of Frontal Fibrosing Alopecia: Mid Trial Update. Poster presented at the 2025 Fall Clinical Dermatology Conference, Las Vegas, Nevada, Oct 23-26, 2025.

Butera A. Frontal Fibrosing Alopecia Associated with Significantly Lower Quality of Life. HCPLive. June 27, 2022. 

https://www.hcplive.com/view/frontal-fibrosing-alopecia-significantly-lower-qol

Articles

Baricitinib, a JAK inhibitor, has shown promising results in reducing disease activity in post-menopausal women with frontal fibrosing alopecia, a condition resistant to standard treatments. A 36-week open-label trial demonstrated significant improvements in disease activity and patient-reported outcomes over 12 weeks, with a notable decrease in the Lichen Planopilaris Activity Index and an increase in the PRO Scalp Hair Growth score. However, no significant changes were observed in eyebrow growth or pruritus. Further follow-up is needed to assess long-term benefits and potential hair regrowth.

In this analysis, investigators examined the efficacy of baricitinib in terms of its impact on disease activity and progression of frontal fibrosing alopecia.

Alopecia

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Mid Trial Update Released on Baricitinib for Frontal Fibrosing Alopecia

Daniel Manning, MD: An allergy, asthma, & immunology specialist located in Arizona

Donidalorsen Shows Durable Long-Term Efficacy for HAE, With Daniel Manning, MD

2025 College of Allergy, Asthma, & Immunology (ACAAI) Annual Scientific Meeting 

in Orlando, Florida, Daniel E. Manning, MD, an allergy, asthma, & immunology specialist located in Arizona, presented long-term OASISplus open-label extension and switch data for donidalorsen (DAWNZERA) and what the findings mean for clinicians treating 

 For Dr. Manning, the message is clear: long-term data continue to reinforce donidalorsen’s strong safety and durable efficacy profile.

The US Food & Drug Administration (FDA) approved donidalorsen, an RNA-targeted medicine, as a prophylactic treatment for HAE earlier this year in adults and children aged ≥ 12 years. Ionis Pharmaceuticals announced the approval on August 21, 2025.

 The decision was based on pivotal data from the phase 3 OASIS-HAE and OASISplus trials, along with an ongoing phase 2 open-label extension trial.

In the extension study, donidalorsen performed well, with no new or unexpected safety signals. Patients experienced a 94–95% reduction in monthly attack rates, whether on every-4-week or every-8-week dosing. Manning noted that these reductions are comparable, or even superior, to what has been reported for previous long-term prophylactic options. Patients tended to experience continued improvement the longer they remained on therapy.

“The more you worry about it, the more attacks you're going to have,” Manning told 

 “When you get a product like donidalorsen, and it is working well, you start going, ‘wow, I haven't had as few attacks. I've got an agent that's dosed less frequently than maybe other products I've used before.’ That builds this impetus of ‘I'm doing better, and life is great’ in that I'm not as stressed about dealing with my [HAE], which leads [to] a better quality of life and better control of the disease. The better you're doing, the better you do.”

Switch data from the study added another layer of insight. Patients who transitioned into donidalorsen from other prophylactic agents, including lanadelumab, C1 esterase inhibitors, and berotralstat, maintained disease control without rebound attacks. Most improved further, despite entering the study with relatively low baseline attack rates. More than 80% reported preferring donidalorsen over their prior therapy.

“When asked, ‘Well, do you like donidalorsen better than what you were on before? The vast majority said, ‘Yes, I feel better. I feel like my heart is [under] better control. I'm having fewer attacks. I'm tolerating it really well,” Manning said. “That was very telling in that even though patients were on some very good products, there's always room for improvement in patients who may not be [having an attack] as frequently as we think.”

Manning has no relevant reported disclosures.

Ionis presents new data demonstrating long-term disease control with DAWNZERATM (donidalorsen) at ACAAI 2025 Annual Meeting | Ionis Pharmaceuticals, Inc.. Ionis Pharmaceuticals, Inc. Published 2025. Accessed November 20, 2025. 

https://ir.ionis.com/news-releases/news-release-details/ionis-presents-new-data-demonstrating-long-term-disease-control

Derman C. FDA Approves Donidalorsen to Prevent Hereditary Angioedema Attacks. Hcplive.com. Published August 21, 2025. 

https://www.hcplive.com/view/fda-approves-donidalorsen-to-prevent-hereditary-angioedema-attacks

At ACAAI 2025, Manning highlighted sustained attack reduction and strong patient preference for donidalorsen across long-term and switch data.

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

TRANQUILITY: Pacibekitug Safely Lowers hs-CRP in ASCVD, With Deepak Bhatt, MD

The interleukin-6 (IL-6) inhibitor pacibekitug (TOUR006) has indicated its safety and efficacy in reducing high-sensitivity C-reactive protein (hs-CRP) levels in patients with 

atherosclerotic cardiovascular disease (ASCVD)

, based on results from the phase 2 TRANQUILITY trial.

American Heart Association’s Scientific Sessions 2025

 in New Orleans, Louisiana, by Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai.

Pacibekitug is an investigational long-acting fully human monoclonal antibody against the IL-6 cytokine, in development by Tourmaline Bio. While the TRANQUILITY trial investigated its efficacy in treating ASCVD, pacibekitug is also under development for thyroid eye disease, with plans to expand into abdominal aortic aneurysm in the future.

“We showed incremental benefit in hs-CRP reduction, and hopefully that will translate into cardiovascular event reduction,” Bhatt said in an exclusive interview with 

. “But this wasn’t a trial designed to measure cardiovascular events. TRANQUILITY was designed to look at safety and to look at hs-CRP, and it seemed to be safe and highly efficacious in reducing risk.”

Patients were included in the TRANQUILITY trial if they were ≥18 years old, had a serum hs-CRP level ≥2.0 mg/L and <15 mg/L, and a diagnosis of CKD. Patients were excluded if they exhibited evidence of active infection, had serious infections within 6 months or >1 episode within 18 months, a known history of immunodeficiency, a history of gastrointestinal ulceration or perforation within 12 months, a history of active diverticulitis, inflammatory bowel disease, or GI abscess within 12 months, among other criteria.

The treatment period lasted 6 months, followed by a follow-up period of an additional 6 months. The primary endpoint was median time-averaged percent change in hs-CRP through day 90, adjusting for baseline. The key secondary endpoint was the percentage of participants achieving time-averaged hs-CRP below 2 mg/L through day 90. Additionally, investigators noted the percentage of participants achieving hs-CRP reductions of ≥50%.

Bhatt and colleagues ultimately included 143 patients, stratifying them by CKD stage and randomly assigning them to receive either pacibekitug 25 mg quarterly, 50 mg quarterly, or 15 mg monthly, or placebo, all delivered subcutaneously. Median age was 71 years, and 62% of patients were women. Baseline estimated glomerular filtration rate and hs-CRP were 43 ml/min/1.73m2 and 4.45 mg/L, respectively.

By day 90, the median time-averaged percent reduction in hs-CRP was 86% for the 50 mg dose, 75% for the 25 mg dose, and 85% for the 15 mg dose, versus 15% for the placebo arm (all 

 <.0001). Several patients achieved hs-CRP reductions ≥50%, and the percentage of patients with hs-CRP <1 mg/L at day 90 was 60%, 45%, and 65% for the 50 mg, 25 mg, and 15 mg arms compared to 13% for placebo (all 

Bhatt and colleagues concluded that hs-CRP was reduced significantly across all prespecified groups with pacibekitug. They also observed significant reductions in serum amyloid A, fibrinogen, and lipoprotein(a). The incidence of adverse events was 54% and 56% in the pooled pacibekitug and placebo arms, respectively. The team noted similar findings for serious adverse events (10% vs 11%), infections (24% vs 22%), and serious infections (4% vs 3%). According to the study abstract, pacibekitug is now the first IL-6 inhibitor to demonstrate sustained and significant reductions in hs-CRP with quarterly dosing.

“Our hope is that, on the basis of the TRANQUILITY trial, there will be a phase 3 trial powered to look at cardiovascular end points,” Bhatt said. “That’s really what the purpose of the TRANQUILITY trial was: to see if it looked like the drug was safe, if it looked like there was an advantage potential over other IL-6 inhibitors, and to proceed with phase 3 testing.”

Pergola P, Szarek M, Zayed H, et al. A Phase 2 Multicenter, Randomized Double-Blind, Placebo-Controlled Study of Monthly or Quarterly Subcutaneous Administration of the Interleukin-6 Inhibitor Pacibekitug in Patients With Elevated High-Sensitivity C-Reactive Protein and Chronic Kidney Disease: 90-Day Analyses from TRANQUILITY. Abstract presented at the American Heart Association’s Scientific Sessions 2025. New Orleans, Louisiana. November 8-10, 2025.

Tourmaline Bio, Inc. A Study to Evaluate TOUR006 in Patients With Chronic Kidney Disease and Elevated Hs-CRP (TRANQUILITY). ClinicalTrials.gov Identifier: NCT06362759. Updated November 14, 2025. Accessed November 20, 2025. 

https://clinicaltrials.gov/study/NCT06362759

Mishek S. Tourmaline Bio Announces Positive Topline Results from the Ongoing Phase 2 TRANQUILITY Trial Evaluating Pacibekitug in Patients with Elevated High-Sensitivity C-reactive Protein and Chronic Kidney Disease. Tourmaline Bio. May 20, 2025. Accessed November 20, 2025. 

https://ir.tourmalinebio.com/news-releases/news-release-details/tourmaline-bio-announces-positive-topline-results-ongoing-phase

Bhatt discusses the positive results from the phase 2 trial of quarterly and monthly doses of investigational IL-6 inhibitor pacibekitug.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Atherosclerotic Cardiovascular Disease

Chronic Kidney Disease

Naim Alkhouri, MD, is Chief Academic Officer at Summit Clinical Research and the Director of the Steatotic Liver Disease Program at the Clinical Research Institute of Ohio.

Using Noninvasive Testing to Guide MASH Treatment Decisions, With Naim Alkhouri, MD

The rapid emergence of pharmacologic options for metabolic dysfunction-associated steatohepatitis (MASH) has introduced a new set of clinical challenges, particularly around identifying which patients are appropriate candidates for treatment.

With both resmetirom and semaglutide now approved by the US Food and Drug Administration for patients with F2-F3 fibrosis, professional societies have emphasized the need for careful noninvasive assessment to avoid treating individuals with cirrhosis until more data become available. However, the practical application of these recommendations is not always straightforward, as liver stiffness thresholds commonly used to exclude patients may inadvertently prevent some individuals with advanced fibrosis from receiving therapies that have the potential to reverse disease progression.

“We know from clinical practice that many patients with liver stiffness above 20, between 20 to 25, may actually have stage 3 fibrosis, not cirrhosis, and if you exclude them automatically, they will miss the opportunity to be treated with the treatment that can reverse fibrosis,” Naim Alkhouri, MD, chief academic officer of Summit Clinical Research and director of the Steatotic Liver Program at North Shore Gastroenterology, explained to 

American Association for the Study of Liver Diseases (AASLD) The Liver Meeting 2025

, Alkhouri presented research examining the performance of noninvasive tests (NITs) in identifying F2/F3 or F4 fibrosis in patients with LSM 15-25 kPa in a large multicenter database of patients with biopsy-proven MASH.

Patients with LSM 15-20 kPa or LSM 20-25 kPa were identified for further analysis. Comparisons were made between those found to have F2/F3 on biopsy versus F4, and NIT performance was compared to biopsy results.

Of 18,402 patients reviewed, 4326 had baseline liver biopsy and LSM results, 882 of whom had LSM between 15-25. Among patients with LSM between 15-20 kPa (n = 586, 66%; n = 354 F2/F3 and n = 232 F4) and 20-25 kPa (n = 296, 34%; n = 141 F2/F3 and n = 155 F4), patients with F4 fibrosis were significantly older (

In patients with LSM 15-20 kPa, investigators noted model performance was highest using Agile 4 (AUC, 0.76; 95% CI, 0.69-0.83), followed by platelet count (AUC, 0.71; 95% CI, 0.66-0.76) and FIB-4 (AUC, 0.69; 95% CI, 0.64-0.75). Among the LSM 20-25 kPa group, platelet count had superior performance (AUC, 0.75; 95% CI, 0.69-0.82), followed by FIB-4 (AUC, 0.73; 95% CI, 0.66-0.80), and Agile 4 (AUC, 0.70; 95% CI, 0.60-0.79).

Combining all tests resulted in an AUC of 0.76 (95% CI, 0.69-0.82) in the 15-20 kPa group and 0.75 (95% CI, 0.66-0.84) in the 20-25 kPa group. To reach ≥90% sensitivity, for the Agile 4 score, a cutoff value of 0.104 was needed in the 15-20 kPa group and 0.099 in the 20-25 kPa group.

“We hope that these recommendations will be useful to providers when they have elevated liver stiffness and they're not sure if they need to proceed with treatment with resmetirom or semaglutide or say no because this patient has cirrhosis,” Alkhouri said.

Editors’ note: Alkhouri reports relevant disclosures with Altimmune, Madrigal Pharmaceuticals, Merck, Novo Nordisk, Rivus, Takeda, and others.

Alkhouri N, Schattenberg J, Patil R, et al. Utility of FIB-4, Agile 4, and Platelet Count to Rule Out Cirrhosis on Biopsy in Patients with LSM Between 15-25 kPa: A Multi-Center Cohort Study. Presented at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting 2025. Washington, DC. November 7-11, 2025.

Brooks A. Resmetirom (Rezdiffra) Receives Historic FDA Approval for Noncirrhotic NASH. HCPLive. March 14, 2024. Accessed November 20, 2025. 

https://www.hcplive.com/view/resmetirom-rezdiffra-receives-historic-fda-approval-for-noncirrhotic-nash

Brooks A. FDA Approves Semaglutide (Wegovy) Injection 2.4 mg for Noncirrhotic MASH. HCPLive. August 15, 2025. Accessed November 20, 2025. 

https://www.hcplive.com/view/fda-approves-semaglutide-wegovy-injection-2-4-mg-for-noncirrhotic-mash

Alkhouri explains the importance of differentiating F3 from cirrhosis and the utility of different noninvasive tests for identifying these patients.

Hepatology

MASH / MASLD

The HCPLive MASH & MASLD page is a comprehensive resource for clinical news and insights on metabolic dysfunction-associated steatotic liver disease and steatohepatitis. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for fatty liver disease, steatohepatitis, and more.

These data highlight a super-response following treatment with delgocitinib cream 20 mg/g in a subgroup of patients with moderate to severe CHE.


Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

Subgroup with Chronic Hand Eczema See ‘Super Response’ with Delgocitinib Cream

University of Colorado Health Sciences Center

A study presented at ACAAI 2025 reveals HAE attacks may start in toddlers, highlighting significant daily burdens and the importance of timely diagnosis and treatment.

HAE Attacks May Begin as Early as 2 Years Old, With Daniel Soteres, MD, PhD

Assistant Professor at the University of Texas Health Science Center at San Antonio

Becker recapped hot topics of discussion during a recent HCPLive clinical forum.

Non-Steroidal Topicals: A Game-Changer for Pediatric Atopic Dermatitis, With Emily Becker, MD

Abigail Brooks is an assistant managing editor for 

She joined MJH Life Sciences in August 2023 shortly after graduating from Monmouth University where she earned her BA in Communication with a concentration in Public Relations/Journalism and later an MA in Interactive Digital Media. She enjoys traveling, running, and reading books. She can be reached at abrooks@mjhlifesciences.com.

The living guideline incorporates new medications and the latest data to make recommendations for moderate-to-severely active CD care.

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

Inflammatory Bowel Disease

On the HCPLive inflammatory bowel disease page, resources on the topics of medical news and expert insight into IBD can be found. Content includes articles, interviews, videos, podcasts, and breaking news on IBD and more.

AGA Releases Updated Clinical Crohn’s Disease Guideline Reflecting New Therapies

James Ip, MD, is a professor and cardiologist at Weill Cornell Medicine.

Ip highlights the uniform safety of patient-administered etripamil nasal spray across a series of phase 2 and 3 studies.

Self-Administered Nasal Etripamil Restores Sinus Rhythm Safely, With James Ip, MD

The SCALE-UP study, assessing patients with atopic dermatitis treated with upadacitinib, points to rapid real‐world efficacy findings on this medication.

SCALE-UP: Findings on Real-World Use of Upadacitinib in Atopic Dermatitis

Jonathan A. Bernstein, MD: University of Cincinnati

New phase 2 data reveals povorcitinib effectively reduces itch and hives in chronic spontaneous urticaria, showing promise as a treatment option.

Povorcitinib 75 mg Rapidly Reduces Itch and Hives in CSU, With Jonathan Bernstein, MD

At the Fall Clinical Dermatology Conference, this session provided clinical pearls to clinicians in the pediatric dermatology space.

Clinical Pearls in Pediatric Dermatology Highlighted in 2025 Fall Clinical Conference

Mazen Noureddin, MD, MHSc, is a professor of medicine and a transplant hepatologist at Houston Methodist and director of the Houston Research Institute.

Noureddin explains HU6’s mechanism of action and phase 2 data presented at AASLD The Liver Meeting supporting its use in MASH.

Understanding HU6 and Its Emerging Role in MASH, With Mazen Noureddin, MD, MHSc

Gulati discusses how cardiologists should change their standard care practices to include and educate patients, which will reduce treatment burden and improve adherence.

Heart Failure

The HCPLive heart failure page is a resource for medical news and expert insights on HF. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for heart disease, reduced and preserved ejection fraction, and more.

Latest News

PREVAIL: Felzartamab’s Sustained Clinical Outcomes In IgAN, With Jurgen Floege, MD

Mid Trial Update Released on Baricitinib for Frontal Fibrosing Alopecia

Donidalorsen Shows Durable Long-Term Efficacy for HAE, With Daniel Manning, MD

TRANQUILITY: Pacibekitug Safely Lowers hs-CRP in ASCVD, With Deepak Bhatt, MD

Using Noninvasive Testing to Guide MASH Treatment Decisions, With Naim Alkhouri, MD